THAT IS A NICE HONOR.I WONDER WHAT ELSE IS UP.
Sarepta Therapeutics, Inc. [SRPT], a developer of innovative RNA-based therapeutics, will visit the NASDAQ MarketSite in Times Square to celebrate its recent positive 36 week clinical data from its Phase IIb study of eteplirsen for the treatment of Duchenne muscular dystrophy. Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases.
In honor of the occasion, Chris Garabedian, CEO will ring the Closing Bell.
NASDAQ MarketSite -- 4 Times Square -- 43rd & Broadway -- Broadcast Studio
Wednesday, August 8, 2012 -- 3:45 p.m. to 4:00 p.m. ET
The obvious question... What else could CG be doing in NY. Perhaps an enterprise changing deal is on the table. By my count, he should already have the 40 week 6 minute walk data and the 44 week data should be close at hand. A continued positive trend would make the CEO feel very bullish. The bell decision may truly be symbolic and is certainly a smart move.